Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
phosphodiesterase type 5 inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
2012 |
| gptkbp:ATCCode |
G04BE10
|
| gptkbp:brand |
Spedra
Stendra |
| gptkbp:CASNumber |
330784-47-9
|
| gptkbp:contraindication |
nitrate medications
|
| gptkbp:developedBy |
gptkb:Mitsubishi_Tanabe_Pharma
|
| gptkbp:eliminationHalfLife |
5 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C23H26ClN7O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
avanafil
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits phosphodiesterase type 5
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
Not for use in women
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
back pain nasal congestion flushing |
| gptkbp:usedFor |
erectile dysfunction
|
| gptkbp:bfsParent |
gptkb:vardenafil
|
| gptkbp:bfsLayer |
6
|